Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Hold at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Up 3.3 %

ORMP stock opened at $2.48 on Thursday. The company’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $2.45. Oramed Pharmaceuticals has a 12-month low of $1.67 and a 12-month high of $3.67. The firm has a market cap of $100.76 million, a price-to-earnings ratio of 9.54 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.01 by $0.21. Research analysts expect that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Murchinson Ltd. grew its holdings in shares of Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after buying an additional 320,495 shares during the last quarter. XTX Topco Ltd bought a new position in Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals during the 1st quarter worth approximately $68,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.